DexCom, Inc.
DXCMNASDAQHealthcare● Active
$72.86
+$0.27(+0.37%)
Market Cap$28.1B
P/E Ratio—
52W High$89.98
52W Low$54.11
DexCom, Inc. (DXCM) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
DXCM · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: Apr 30, 2026EPS Actual
$0.56
Est. $0.47 · +20.3%
Revenue
$1.19B
Est. $1.17B · +1.5%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
Apr 30, 2026
After Market Close
▲ Beat EPS▲ Beat Revenue🔥 4-Quarter EPS Beat Streak
DXCM reports quarterly as a NASDAQ-listed Medical - Devices company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Rev. $7.60B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
Rev. Est.$7.60B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Jul 29, 2026 | $0.60 | — | — | — | $1.29B | — |
| ▲ Q2 FY2026 | Apr 30, 2026 | $0.47 | $0.56 | +20.3% | $1.19B | $1.17B | +1.5% |
| ▲ Q1 FY2026 | Feb 12, 2026 | $0.65 | $0.68 | +4.6% | $1.26B | $1.25B | +0.9% |
| ▲ Q4 FY2025 | Oct 30, 2025 | $0.58 | $0.61 | +5.9% | $1.21B | $1.18B | +2.2% |
| ▲ Q3 FY2025 | Jul 30, 2025 | $0.44 | $0.48 | +8.2% | $1.16B | $1.12B | +2.9% |
| ▼ Q2 FY2025 | May 1, 2025 | $0.33 | $0.32 | -2.2% | $1.04B | $1.02B | +1.8% |
| ▼ Q1 FY2025 | Feb 13, 2025 | $0.48 | $0.45 | -6.1% | $1.11B | $1.11B | +0.4% |
| ▲ Q4 FY2024 | Oct 24, 2024 | $0.44 | $0.45 | +2.3% | $0.99B | $0.99B | +0.4% |
Q3 FY2026
Jul 29, 2026
EPS Actual
—
EPS Est.
$0.60
EPS Surpr.
—
Revenue
—
Q2 FY2026
Apr 30, 2026Beat
EPS Actual
$0.56
EPS Est.
$0.47
EPS Surpr.
+20.3%
Revenue
$1.19B
Q1 FY2026
Feb 12, 2026Beat
EPS Actual
$0.68
EPS Est.
$0.65
EPS Surpr.
+4.6%
Revenue
$1.26B
Q4 FY2025
Oct 30, 2025Beat
EPS Actual
$0.61
EPS Est.
$0.58
EPS Surpr.
+5.9%
Revenue
$1.21B
Q3 FY2025
Jul 30, 2025Beat
EPS Actual
$0.48
EPS Est.
$0.44
EPS Surpr.
+8.2%
Revenue
$1.16B
Q2 FY2025
May 1, 2025Miss
EPS Actual
$0.32
EPS Est.
$0.33
EPS Surpr.
-2.2%
Revenue
$1.04B
Q1 FY2025
Feb 13, 2025Miss
EPS Actual
$0.45
EPS Est.
$0.48
EPS Surpr.
-6.1%
Revenue
$1.11B
Q4 FY2024
Oct 24, 2024Beat
EPS Actual
$0.45
EPS Est.
$0.44
EPS Surpr.
+2.3%
Revenue
$0.99B
Analyst Estimates
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $1.07 | $1.10 | $1.13 | 7 |
| Q3 FY2028 | $0.93 | $0.96 | $0.98 | 12 |
| Q2 FY2028 | $0.85 | $0.87 | $0.89 | 7 |
| Q1 FY2028 | $0.70 | $0.72 | $0.74 | 7 |
| Q4 FY2027 | $0.85 | $0.87 | $0.90 | 6 |
| Q3 FY2027 | $0.77 | $0.79 | $0.81 | 7 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $1.7B | $1.8B | $1.8B | 6 |
| Q3 FY2028 | $1.6B | $1.6B | $1.7B | 6 |
| Q2 FY2028 | $1.6B | $1.6B | $1.6B | 6 |
| Q1 FY2028 | $1.4B | $1.4B | $1.5B | 6 |
| Q4 FY2027 | $1.5B | $1.6B | $1.6B | 7 |
| Q3 FY2027 | $1.5B | $1.5B | $1.5B | 7 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | Apr 30, 2026 | +20.3% | $57.56 | $59.55 | +3.46% |
| ▲ Q1 FY2026 | Feb 12, 2026 | +4.6% | $68.15 | $65.08 | -4.50% |
| ▲ Q4 FY2025 | Oct 30, 2025 | +5.9% | $68.18 | $68.20 | +0.03% |
| ▲ Q3 FY2025 | Jul 30, 2025 | +8.2% | $89.35 | $89.06 | -0.32% |
| ▼ Q2 FY2025 | May 1, 2025 | -2.2% | $71.38 | $70.26 | -1.57% |
| ▼ Q1 FY2025 | Feb 13, 2025 | -6.1% | $83.87 | $84.09 | +0.26% |
| ▲ Q4 FY2024 | Oct 24, 2024 | +2.3% | $72.48 | $74.85 | +3.27% |
| ▲ Q3 FY2024 | Jul 25, 2024 | +10.3% | $111.94 | $107.85 | -3.65% |
Q2 FY2026+3.46%
Report Date
Apr 30, 2026
EPS Beat/Miss
+20.3%
Price Before
$57.56
Price After
$59.55
Q1 FY2026-4.50%
Report Date
Feb 12, 2026
EPS Beat/Miss
+4.6%
Price Before
$68.15
Price After
$65.08
Q4 FY2025+0.03%
Report Date
Oct 30, 2025
EPS Beat/Miss
+5.9%
Price Before
$68.18
Price After
$68.20
Q3 FY2025-0.32%
Report Date
Jul 30, 2025
EPS Beat/Miss
+8.2%
Price Before
$89.35
Price After
$89.06
Q2 FY2025-1.57%
Report Date
May 1, 2025
EPS Beat/Miss
-2.2%
Price Before
$71.38
Price After
$70.26
Q1 FY2025+0.26%
Report Date
Feb 13, 2025
EPS Beat/Miss
-6.1%
Price Before
$83.87
Price After
$84.09
Q4 FY2024+3.27%
Report Date
Oct 24, 2024
EPS Beat/Miss
+2.3%
Price Before
$72.48
Price After
$74.85
Q3 FY2024-3.65%
Report Date
Jul 25, 2024
EPS Beat/Miss
+10.3%
Price Before
$111.94
Price After
$107.85
Avg Beat Reaction-0.28%
Avg Miss Reaction-0.66%
Beat Rate6 / 8 quarters
Largest Move-4.50% (Q1 FY2026)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: DXCM ends December
DexCom, Inc. (DXCM) most recently reported earnings on April 30, 2026 for Q2 FY2026, posting EPS of $0.56 — beating the analyst consensus of $0.47 by +20.3%. DXCM has beaten EPS estimates for 4 consecutive quarters. The next DXCM earnings date is expected around September 1, 2026.
Each quarter, investors track DXCM earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. DXCM revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
DXCM's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
DXCM earnings · 5 questionsDexCom, Inc.'s next earnings report is expected around September 1, 2026. DXCM typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; DXCM historically reports after market close (AMC).
DXCM earnings datewhen is DXCM earningsDXCM next earnings datewhen does DXCM report earningsDXCM earnings calendar
▸ Source: FMP · DexCom, Inc. SEC filings · US GAAP · DexCom, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026